<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Inflammatory arthritis drug monitoring</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Inflammatory arthritis drug monitoring</h1>
<div class="graphic"><div class="figure"><div class="ttl">Inflammatory arthritis drug monitoring</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"> </colgroup> <tbody> <tr> <td class="subtitle1">Drug class</td> <td class="subtitle1">Drugs</td> <td class="subtitle1">Ongoing monitoring via system review and physical examination<sup>*</sup></td> <td class="subtitle1">Ongoing laboratory monitoring and other testing<sup>¶Δ</sup></td> </tr> <tr> <td> </td> <td>Nonsteroidal antiinflammatory drugs (eg, naproxen, ibuprofen, aspirin)</td> <td>Dyspepsia, nausea/vomiting, abdominal pain, edema, blood pressure</td> <td>CBC and complete metabolic panel (electrolytes, creatinine, albumin, transaminases) every 6 months</td> </tr> <tr> <td> </td> <td>Glucocorticoids</td> <td>Mood, weight gain, visual changes, weakness, polyuria, polydipsia, edema, infection, blood pressure</td> <td>Diabetes screening, lipids, bone mineral density testing</td> </tr> <tr class="highlight_lght_gray_text"> <td rowspan="6"><strong>Conventional synthetic disease-modifying antirheumatic drugs (csDMARDS)</strong></td> <td>Hydroxychloroquine</td> <td>Visual change, skin color change, paresthesia<sup>◊</sup></td> <td>Ophthalmologic evaluation for retinal toxicity<sup>◊</sup></td> </tr> <tr class="highlight_lght_gray_text"> <td>Sulfasalazine</td> <td>Headache, nausea, diarrhea, photosensitivity, symptoms of myelosuppression, hepatotoxicity, rash</td> <td>CBC, aminotransferases and creatinine every 2 to 4 weeks for the first 3 months or after increasing the dose, every 8 to 12 weeks for months 3 to 6, then every 12 weeks</td> </tr> <tr class="highlight_lght_gray_text"> <td>Methotrexate<sup>§</sup></td> <td>Stomatitis, alopecia, diarrhea, nausea/vomiting, flu-like symptoms, shortness of breath, symptoms of myelosuppression, hepatotoxicity, infection, lymph node swelling, pregnancy</td> <td>CBC, aminotransferases, and creatinine every 2 to 4 weeks for the first 3 months or after increasing the dose, every 8 to 12 weeks for months 3 to 6, then every 12 weeks</td> </tr> <tr class="highlight_lght_gray_text"> <td>Leflunomide<sup>§</sup></td> <td>Nausea/vomiting, diarrhea, shortness of breath, paresthesia, hepatotoxicity, weight loss, blood pressure, pregnancy</td> <td>CBC, aminotransferases, and creatinine every 2 to 4 weeks for the first 3 months or after increasing the dose, every 8 to 12 weeks for months 3 to 6, then every 12 weeks</td> </tr> <tr class="highlight_lght_gray_text"> <td>Minocycline</td> <td>Hyperpigmentation, dizziness, falls</td> <td>None after baseline</td> </tr> <tr class="highlight_lght_gray_text"> <td>Azathioprine</td> <td>Diarrhea, nausea/vomiting, symptoms of myelosuppression, infection</td> <td>CBC and platelet count every 1 to 2 weeks, with changes in dose every 1 to 3 months thereafter</td> </tr> <tr> <td rowspan="7"><strong>Biologic DMARDs (bDMARDs)</strong></td> <td>TNF inhibitors (eg, etanercept, infliximab, adalimumab, certolizumab pegol, and golimumab)</td> <td>Infection, malignancy, demyelination, congestive heart failure, autoimmune phenomenon</td> <td>No routine laboratory monitoring (unless also receiving a concurrent conventional DMARD)</td> </tr> <tr> <td>IL-6 inhibitors (eg, tocilizumab and sarilumab)</td> <td>Infection, symptoms of myelosuppression (PMNs and platelets), demyelination, hepatotoxicity, gastrointestinal perforations</td> <td>CBC with differential (neutrophils) and LFTs every 4 to 8 weeks until stable, then every 3 months. Lipids 4 to 8 weeks after starting therapy, then every 6 months.</td> </tr> <tr> <td>Anti-CD20 antibodies (ie, rituximab)</td> <td>Infection, PML, symptoms of neutropenia</td> <td>CBC every 2 to 4 months</td> </tr> <tr> <td>CTLA4 Ig inhibitor (ie, abatacept)</td> <td>Infection, COPD exacerbation, malignancy</td> <td>No routine laboratory monitoring (unless also receiving a concurrent conventional DMARD)</td> </tr> <tr> <td>IL-12/23 inhibitor (ie, ustekinumab)</td> <td>Nasopharyngitis, upper respiratory infection, headache</td> <td>No routine laboratory monitoring (unless also receiving a concurrent conventional DMARD)</td> </tr> <tr> <td>IL-17 injhibitors (ie, ixekizumab, secukinumab, brodalumab, bimekizumab)</td> <td>Infection, nasopharyngitis, headache</td> <td>No routine laboratory monitoring (unless also receiving a concurrent conventional DMARD)</td> </tr> <tr> <td>IL-23 inhibitor (ie, guselkumab, risankizumab)</td> <td>Upper respiratory infection, headache, fatigue, injection site reactions</td> <td>No routine laboratory monitoring (unless also receiving a concurrent conventional DMARD)</td> </tr> <tr class="highlight_lght_gray_text"> <td rowspan="2"><strong>Targeted synthetic DMARDs (tsDMARDs)</strong></td> <td>JAK inhibitors (eg, tofacitinib, baricitinib, and upadacitinib)</td> <td>Infection, zoster, symptoms of myelosuppression, hepatotoxicity, malignancy, gastrointestinal perforation</td> <td>CBC with differential, creatinine, LFTs (transaminases, albumin, bilirubin) every month for 3 months, then every 3 months; lipids 6 to 8 weeks after drug start</td> </tr> <tr class="highlight_lght_gray_text"> <td>PDE4 inhibitor (ie, apremilast)</td> <td>Diarrhea, nausea/vomiting, headache</td> <td>No routine laboratory monitoring (unless also receiving a concurrent conventional DMARD)</td> </tr> </tbody></table></div><div class="graphic_lgnd"><p>These drugs are commonly used for the treatment of inflammatory arthritis (eg, rheumatoid arthritis, psoriatic arthritis, spondyloarthritis). Not all drugs are approved for all uses by all regulatory agencies.</p>
These are general guidelines. Patients should be assessed on an individual basis to determine if they require additions or other modifications to the monitoring noted in this table.</div><div class="graphic_footnotes"><p>CBC: complete blood cell count (hematocrit, hemoglobin, white blood cell count, including differential white blood cell count and platelet counts); COPD: chronic obstructive pulmonary disease; IL-6: interleukin 6; JAK: Janus kinase; LFTs: liver function tests; PDE4: phosphodiesterase-4; PML: progressive multifocal leukoencephalopathy; PMNs: polymorphonuclear leukocytes; TB: tuberculosis; TNF: tumor necrosis factor.</p>
<p>* Confirm that immunizations are up to date in all patients.</p>
<p>¶ Screening for latent TB prior to all biologic DMARDs and prior to use of a JAK inhibitor, and repeat TB testing in patients at increased risk of or with known exposure to TB and patients treated for latent TB with potential ongoing exposure.</p>
<p>Δ Patients receiving a biologic DMARD or JAK inhibitor should also continue appropriate monitoring for concurrent conventional DMARD therapies.</p>
<p>◊ Refer to the UpToDate topic review on antimalarial drugs in the treatment of rheumatic disease for a detailed discussion of appropriate screening procedures for hydroxychloroquine-related ophthalmologic toxicity.</p>
§ In patients receiving methotrexate and leflunomide in combination: CBC, creatinine, albumin, and transaminases every 2 to 4 weeks for the first 3 months or following dose increase, every 4 weeks for the next 3 months, then every 3 months.</div><div class="graphic_reference">Adapted from:
<ol>
<li>American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996; 39:723.</li>
<li>American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46:328.</li>
<li>Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59:762.</li>
<li>Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 2016; 68:1.</li>
</ol></div><div id="graphicVersion">Graphic 142892 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
